Subtype
Pancreatic Exocrine Neoplasm
CI-CAN-00003563Explore in graph →
Non-malignant372 active trials5 approved drugs27 evidence items
- NCIt
- C4445
Loading cancer entity…
Subtype
CI-CAN-00003563Explore in graph →
Clinical trials
977 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05074472 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | completed | Phase 1 / Phase 2 | 35 | ZielBio, Inc.INDUSTRY | 1 | Jan 29, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06168552 | Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer(CISPD-6) | unknown | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 23 | Albert Einstein College of MedicineOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02527434 | Study of Tremelimumab in Patients With Advanced Solid Tumors | completed | Phase 2 | 64 | AstraZenecaINDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT04565327 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 7 | Zhen Wang, MDOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT02178436 | Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 15 | Mohammed Najeeb Al HallakOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT00020345 | Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas | completed | Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04983407 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 34 | Aravive, Inc.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT02383433 | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer | terminated | Phase 2 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT03490760 | Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas | terminated | Phase 2 | 9 | Baptist Health South FloridaOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT01959672 | Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer | completed | Phase 2 | 11 | University of NebraskaOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03611556 | MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. | completed | Phase 1 / Phase 2 | 213 | MedImmune LLCINDUSTRY | 4 | Oct 3, 2023 | clinicaltrials |
| NCT02427841 | Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT01726582 | Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") | completed | Phase 2 | 229 | Medical College of WisconsinOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT02324543 | Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT02047513 | Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer(NEONAX) | completed | Phase 2 | 127 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02042378 | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | completed | Phase 2 | 19 | pharmaand GmbHINDUSTRY | 2 | Jun 13, 2023 | clinicaltrials |
| NCT05083247 | Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma(STEREOPAC) | recruiting | Phase 2 | 256 | Erasme University HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT02620865 | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT02194829 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02806687 | Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer(THERGAP-02) | completed | Phase 2 | 68 | University Hospital, ToulouseOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03717298 | Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 30 | Catalysis SLINDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03331562 | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | completed | Phase 2 | 24 | Translational Genomics Research InstituteOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT02564146 | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine(ALPACA) | completed | Phase 2 | 325 | AIO-Studien-gGmbHOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT02562716 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 19, 2022 | clinicaltrials |
| NCT03723915 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | terminated | Phase 2 | 17 | Northwestern UniversityOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT01547260 | Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer(LENAGEM) | completed | Phase 1 / Phase 2 | 34 | Maria LiljeforsOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT05181605 | Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors | unknown | Phase 2 / Phase 3 | 116 | Instituto de investigación e innovación biomédica de CádizOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT02839343 | Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer | unknown | Phase 2 | 126 | Alliance for Clinical Trials in OncologyOTHER | 2 | May 24, 2022 | clinicaltrials |
| NCT02850874 | HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT02178709 | A Phase II Study of Neoadjuvant FOLFIRINOX | completed | Phase 2 | 48 | Indiana UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05268692 | Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP | recruiting | Phase 2 / Phase 3 | 500 | Kochi UniversityOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03331640 | A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy(PANTHEON) | terminated | Phase 2 | 67 | AIO-Studien-gGmbHOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04652206 | Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.(PANTAX-Ib) | unknown | Phase 1 / Phase 2 | 18 | Scandion Oncology A/SINDUSTRY | 2 | Dec 29, 2021 | clinicaltrials |
| NCT02125136 | Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer(NEOLAP) | completed | Phase 2 | 168 | AIO-Studien-gGmbHOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT01660711 | A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | completed | Phase 2 | 22 | Endeavor HealthOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT03410914 | Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy(PATCH-DP) | completed | Phase 2 | 52 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT05066802 | A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma | unknown | Phase 2 | 27 | Yonsei UniversityOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT04718701 | Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer(ATNPA) | unknown | Phase 2 | 53 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01666730 | Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer | completed | Phase 2 | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT03528785 | A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer(nITRo) | unknown | Phase 2 | 67 | Centro Ricerche Cliniche di VeronaOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT01676259 | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer(PROTACT) | unknown | Phase 2 | 80 | Silenseed LtdINDUSTRY | 2 | Jul 2, 2021 | clinicaltrials |
| NCT03451773 | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2021 | clinicaltrials |
| NCT03188991 | Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms | completed | Phase 2 | 20 | NanOlogy, LLCINDUSTRY | 1 | Jun 14, 2021 | clinicaltrials |
| NCT00031694 | Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2021 | clinicaltrials |
| NCT02562898 | Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 18 | Margaret TemperoOTHER | 1 | May 6, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Feb 5, 2024source: clinicaltrials